Related Experiment Video
Updated: Jan 17, 2026

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Administration of Nivolumab Plus FOLFOX Therapy to a Patient with Gastric Cancer Undergoing Hemodialysis
Taichi Yoshida1, Naoaki Kodama1,2, Tomohiro Matsumoto1
1Department of Clinical Oncology, Graduate School of Medicine, Akita University, Japan.
Abstract:
The optimal dose of chemotherapy for patients undergoing hemodialysis remains unclear. A 65-year-old man with diabetic nephropathy was treated with nivolumab plus modified FOLFOX6 therapy for recurrent gastric cancer with liver metastases. Oxaliplatin was reduced to 65 mg/m2, continuous infusion of 5-fluorouracil was initiated at 2,000 mg/m2, and bolus administration was discontinued. No nivolumab was administrated. Dose modification and discontinuation were performed depending on the patient's general condition and blood test during the treatment course. He received standard chemotherapy for gastric cancer; however, it was ineffective because of ascites and elevated CA125 levels.
Related Concept Videos
Hemodialysis III: Nursing Management
Hemodialysis II: Procedure and Complications
Kidney Transplant III: Nursing Management
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Peritoneal Dialysis III: Nursing Management
Chronic Kidney Disease IV: Nursing Management

